药代动力学研究在评估标准剂量抗结核药物暴露-反应关系中的应用。
The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.
作者信息
Sekaggya-Wiltshire Christine, Lamorde Mohammed, Kiragga Agnes N, Dooley Kelly E, Kamya Moses R, Kambugu Andrew, Fehr Jan, Manabe Yukari C, Castelnuovo Barbara
机构信息
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
出版信息
Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7.
Abstract
Tuberculosis (TB) is a major public health problem. Many countries still fall below the minimum World Health Organization (WHO) TB treatment target success rate. There is conflicting evidence about whether concentrations of anti-tuberculosis drugs given at standard doses have an effect on treatment outcomes. The current data correlating anti-TB drug concentrations and treatment outcome is limited. This article summarized the existing literature and their utility in evaluating the association between each anti-TB drug's concentrations using current target concentrations and treatment outcomes in patients with pulmonary tuberculosis receiving standard WHO-recommended dosing.
摘要
结核病是一个重大的公共卫生问题。许多国家的结核病治疗成功率仍低于世界卫生组织（WHO）设定的最低目标。关于标准剂量的抗结核药物浓度是否会对治疗结果产生影响，目前存在相互矛盾的证据。目前将抗结核药物浓度与治疗结果相关联的数据有限。本文总结了现有文献及其在评估接受WHO推荐标准剂量治疗的肺结核患者中，每种抗结核药物浓度与当前目标浓度和治疗结果之间关联的效用。
相似文献
1
The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.药代动力学研究在评估标准剂量抗结核药物暴露-反应关系中的应用。
Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7.
2
Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.固定剂量吡嗪酰胺方案的可行性及其对结核病患者全身药物暴露和肝脏安全性的影响。
Antimicrob Agents Chemother. 2012 Nov;56(11):5442-9. doi: 10.1128/AAC.05988-11. Epub 2012 Jul 9.
3
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
4
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.优化一线抗结核药物的治疗效果：治疗药物监测的作用
Eur J Clin Pharmacol. 2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4. Epub 2016 Jun 15.
5
Optimizing the clinical pharmacology of tuberculosis medications.优化抗结核药物的临床药理学。
Clin Pharmacol Ther. 2015 Oct;98(4):387-93. doi: 10.1002/cpt.180. Epub 2015 Jul 22.
6
Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.高剂量抗结核药物治疗结核病：机制和结果。
Ann Clin Microbiol Antimicrob. 2017 Oct 3;16(1):67. doi: 10.1186/s12941-017-0239-4.
7
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.《2006年抗结核药物国际共识指南：肺结核、肺外结核及特殊情况结核病的管理》
J Assoc Physicians India. 2006 Mar;54:219-34.
8
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.肺结核患者左氧氟沙星个体化给药的群体药代动力学模型和有限采样策略。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01092-18. Print 2018 Dec.
9
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.PA-824 在涂阳肺结核患者中的早期杀菌活性和药代动力学。
Antimicrob Agents Chemother. 2010 Aug;54(8):3402-7. doi: 10.1128/AAC.01354-09. Epub 2010 May 24.
10
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.异烟肼的生理药代动力学模型及其在结核病个体化化疗中的应用
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6134-45. doi: 10.1128/AAC.00508-16. Print 2016 Oct.
引用本文的文献
1
Timing of recurrence after treatment of pulmonary TB.肺结核治疗后复发的时间
IJTLD Open. 2024 Oct 1;1(10):456-465. doi: 10.5588/ijtldopen.24.0222. eCollection 2024 Oct.
2
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.NAT2、GSTM1和CYP2E1基因多态性对肺结核患者异烟肼及其代谢产物血药浓度的影响以及暴露-反应关系评估。
Front Pharmacol. 2024 Mar 22;15:1332752. doi: 10.3389/fphar.2024.1332752. eCollection 2024.
3
Multidrug-resistant tuberculosis.耐多药结核病。
Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
4
Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance.估算劣质抗结核药物的流行情况：全球结核病控制和耐药性面临的一个被忽视的风险。
BMJ Glob Health. 2023 Jul;8(7). doi: 10.1136/bmjgh-2023-012039.
5
Clinical impact of plasma concentrations of first-line antituberculosis drugs.一线抗结核药物血浆浓度的临床影响。
S Afr Med J. 2023 Mar 2;113(3):148-153. doi: 10.7196/SAMJ.2023.v113i3.16761.
6
The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review.一线抗结核药物的药代动力学对治疗结果的影响：一项系统评价
Clin Pharmacol. 2021 Jan 12;13:1-12. doi: 10.2147/CPAA.S289714. eCollection 2021.
7
A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.一项关于一线抗结核药物浓度与治疗结局的系统评价和荟萃分析。
Int J Tuberc Lung Dis. 2020 Jan 1;24(1):48-64. doi: 10.5588/ijtld.19.0025.
8
Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes.利福平浓度低于治疗水平与结核病治疗不良结局相关。
Clin Infect Dis. 2020 Mar 17;70(7):1463-1470. doi: 10.1093/cid/ciz380.
9
Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.遗传变异对南非复发性肺结核患者利福平和异烟肼药代动力学的影响。
Pharmacogenomics. 2019 Mar;20(4):225-240. doi: 10.2217/pgs-2018-0166. Epub 2019 Feb 15.
本文引用的文献
1
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.肺结核中的浓度依赖性拮抗作用与培养转化
Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.
2
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.高剂量利福平、莫西沙星和SQ109治疗结核病：一项多组、多阶段随机对照试验。
Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
3
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.血清中抗结核药物水平及其对结核病治疗结果的影响。
Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8. doi: 10.1128/AAC.00693-15. Print 2016 Jan.
4
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.结核病患者中利福平治疗药物监测的药代动力学建模与最佳采样策略
Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.
5
Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.异烟肼（INH）和利福平（RMP）的血清药物浓度可预测肺结核患者两个月的痰培养结果。
Int J Tuberc Lung Dis. 2015 Feb;19(2):210-5. doi: 10.5588/ijtld.14.0405.
6
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.药代动力学与最低抑菌浓度的非线性相互作用对痰菌杀灭率的影响，作为结核病杀菌效果的一个指标
Antimicrob Agents Chemother. 2015 Jan;59(1):38-45. doi: 10.1128/AAC.03931-14. Epub 2014 Oct 13.
7
Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.剂量、合并症及食物对秘鲁结核病患者异烟肼药代动力学的影响。
Antimicrob Agents Chemother. 2014 Dec;58(12):7164-70. doi: 10.1128/AAC.03258-14. Epub 2014 Sep 15.
8
Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.一线抗结核药物2小时血浆浓度的临床意义：一项前瞻性观察研究。
J Antimicrob Chemother. 2014 Oct;69(10):2841-7. doi: 10.1093/jac/dku210. Epub 2014 Jun 16.
9
Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.一线抗结核药物和莫西沙星的群体药代动力学及有限采样策略。
Int J Antimicrob Agents. 2014 Sep;44(3):229-34. doi: 10.1016/j.ijantimicag.2014.04.019. Epub 2014 Jun 9.
10
Therapeutic drug monitoring in the treatment of tuberculosis: an update.结核病治疗中的治疗药物监测：更新。
Drugs. 2014 Jun;74(8):839-54. doi: 10.1007/s40265-014-0222-8.
Zotero 插件